We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Cord Blood Outperforms Matched Donor in Bone Marrow Transplants

By LabMedica International staff writers
Posted on 08 Aug 2016
A common treatment for blood cancers is to erase a patient's leukemic blood system and then regrow a new blood system using donor blood stem cells. More...
The closer the match between donor cells and a patient's blood system, the less chance the new blood system will attack the patient's tissues which reduces the chance of graft - versus - host disease.

There are four possible sources of donor cells: a matched, related donor, commonly a close family member, a matched, unrelated donor from a database of 25 million people who have agreed to donate, umbilical cord blood from a bank of stored samples, and haploidentical transplant which is a promising technique requiring only a half match with a related donor.

Scientists at the University of Colorado Denver (Aurora, CO, USA) compared 51 consecutive patients receiving umbilical cord blood transplants (CBT) with 57 consecutive patients receiving matched, unrelated donors (MUD). The incidence of severe chronic graft-versus-host disease was 44% in patients who had received transplants from MUD and 8% in patients who had received CBT.

At three years post-transplant, in addition to other difference in severe chronic graft-versus-host disease (cGVHD), overall rates of cGVHD were 68% following MUD and 32% following CBT. Again at three years, patients receiving CBT had been off immunosuppression since a median 268 days from transplant; patients receiving MUD had not ceased immunosuppression to a degree that allowed scientists to determine the median.

Jonathan Gutman, MD, the senior investigator and lead author, said, “When you do an allogeneic transplant, when someone else is the donor, the new blood system has the potential to attack the patient. This is graft-versus-host disease, which can be debilitating and even fatal. Our results show that, long term, receiving a cord blood transplant is less likely than receiving a transplant from an unrelated, matched donor to result in graft-versus-host disease. As a result, we have chosen to use cord blood as our first choice in cases where a matched, related donor is unavailable.” The study was published on July 11, 2016, in the journal Bone Marrow Transplantation.

Related Links:
University of Colorado Denver



New
Gold Member
Hybrid Pipette
SWITCH
Collection and Transport System
PurSafe Plus®
Human Estradiol Assay
Human Estradiol CLIA Kit
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: Private equity firms Blackstone and TPG have joined forces to acquire Hologic in a major healthcare deal (Photo courtesy of Hologic)

Hologic to be Acquired by Blackstone and TPG

Hologic (Marlborough, MA, USA) has entered into a definitive agreement to be acquired by funds managed by Blackstone (New York, NY, USA) and TPG (San Francisco, CA, USA) in a transaction valued at up to... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.